These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19928326)

  • 21. FDA notifications. Zidovudine approved for pediatric use.
    AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19928325
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA notifications. FDA approved pediatric efficacy supplement for Retrovir syrup.
    AIDS Alert; 2008 Nov; 23(11):128. PubMed ID: 19043870
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA notifications. Tentative approval granted for lamivudine/stavudine.
    AIDS Alert; 2008 Aug; 23(8):92-3. PubMed ID: 18727174
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA notifications. Abacavir approved for pediatric patients.
    AIDS Alert; 2009 Feb; 24(2):21-2. PubMed ID: 19222148
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA notifications. FDA gives tentative approval for stavudine, lamivudine & nevirapine tablet.
    AIDS Alert; 2009 Sep; 24(9):105-6. PubMed ID: 19938312
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA notifications. Tentative approval for lamivudine.
    AIDS Alert; 2009 Aug; 24(8):93-4. PubMed ID: 19708084
    [No Abstract]   [Full Text] [Related]  

  • 27. Abacavir: new preparation. Risks limit the value.
    Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA notifications. Abacavir tablet approved for pediatric patients.
    AIDS Alert; 2008 Nov; 23(11):128-9. PubMed ID: 19048648
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA notifications. Fixed dose ART approved by FDA.
    AIDS Alert; 2011 Mar; 26(3):35-6. PubMed ID: 21539043
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA notifications. Ongoing safety review of abacavir, possible MI risk.
    AIDS Alert; 2011 May; 26(5):58-9. PubMed ID: 21649950
    [No Abstract]   [Full Text] [Related]  

  • 31. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
    Moyle GJ; Gazzard BG
    AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
    [No Abstract]   [Full Text] [Related]  

  • 32. Ziagen OK'd by FDA.
    Gaylord G
    Posit Living; 1999 Feb; 8(1):1, 11. PubMed ID: 12492045
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA notifications. FDA approves generic lamivudine.
    AIDS Alert; 2008 Dec; 23(12):142. PubMed ID: 19110688
    [No Abstract]   [Full Text] [Related]  

  • 34. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA notifications. FDA tentatively approves generic lamivudine.
    AIDS Alert; 2007 May; 22(5):57. PubMed ID: 17580368
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA notifications. FDA approves generic abacavir.
    AIDS Alert; 2010 Nov; 25(11):130-1. PubMed ID: 21132857
    [No Abstract]   [Full Text] [Related]  

  • 37. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA notifications. FDA approves generic combination of efavirenz, lamivudine & tenofovir.
    AIDS Alert; 2009 Nov; 24(11):130. PubMed ID: 19960612
    [No Abstract]   [Full Text] [Related]  

  • 39. AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
    Gallant JE
    Hopkins HIV Rep; 2003 Jul; 15(4):1-2. PubMed ID: 14696559
    [No Abstract]   [Full Text] [Related]  

  • 40. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
    Moyle GJ
    AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.